Course of a HBsAg positive liver transplantation in a hepatitis B and D virus coinfected recipient
Journal Title: Annals of Hepatology - Year 2011, Vol 10, Issue 3
Abstract
The increasing demand for transplantation has led to consideration of liver grafts from donors exposed to hepatitis B virus (HBV). Six transplantations of liver grafts from hepatitis B surface antigen (HBsAg) positive donors have been reported; two recipients suffered from HBV/HDV (hepatitis Delta virus) coinfection and were followed up for 10-12 months. Here, we report a 56 months follow-up of a HBV/HDV-coinfected recipient of a HBsAg positive liver graft. Posttransplant combination prophylaxis consisted of hepatitis immunoglobulin, lamivudine and adefovir dipivoxil. HBsAg remained positive during stable posttransplant follow-up and subclinical HDV reinfection with low replication rate was detected at 1 month. Pegylated interferon therapy was introduced after documentation of histological evidence of mild chronic hepatitis, but without virological response after 48 weeks. Finally, antiviral treatment was switched to tenofovir disoproxil fumarate. More than 50 months posttransplant the recipient revealed clinical symptoms of decompensated liver cirrhosis and has been relisted for liver transplantation. In conclusion HBsAg positive liver grafts in HBsAg positive recipients with HDV coinfection may result in virological recurrence and rapid development of liver cirrhosis.
Authors and Affiliations
Hartmut H. J. Schmidt, Jens P. Hölzen, Ralf Bahde, Heiner H. Wolters, C. Thomas Bock, Andreas Lügering, Tilmann Spieker, Norbert Senninger, Jens G. Brockmann
Keywords
Related Articles
- EP ID EP78054
- DOI -
- Views 130
- Downloads 0
Efficacy, tolerability and safety in the treatment of chronic hepatitis C with combination of PEG-Interferon-Ribavirin in daily practice
Background. Efficacy and safety of Pegylated Interferon alfa (PegIFN)-Ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) in routine clinical practice seems to be comparable with results of randomizedcontrolle...
Does the persistently normal aminotransferase levels in hepatitis C still have relevance?
Gilbert’s syndrome and antiviral therapy of hepatitis C
Treatment of chronic hepatitis C with type I interferons and ribavirin can be associated with exacerbation of hepatitis and sometimes liver decompensation. We report two patients with chronic hepatitis C virus infection...
Evaluation the value of markers for prediction of portal vein thrombosis after devascularization
Aim. To evaluate the value of D-dimer and P-selectin in cirrhotic portal hypertension (PHT) patients for prediction of portal vein thrombosis (PVT) after devascularization. Material and methods. 137 patients withcirrhoti...
Outcome of early vs. deferred antiviral treatment for recurrent hepatitis C in liver transplant recipients
The optimal timing to treat recurrent hepatitis-C virus (HCV) after liver transplantation (LT) remains uncertain. We compared the outcome of early (acute phase) and deferred (chronic phase) antiviral treatment for recurr...